Tc1 Cells Percentage in Patients with Cutaneous Leishmaniasis before and after Treatment with Glucantime

Background: Various responses and different prognosis to specific treatment in different patients from one hand, and importance of IFN-γ producer cells on the other hand impressed us to study Tc1. Methods: The study was conducted in Ghaem Medical Center and Bu-Ali Research Institute, Ma...

Full description

Bibliographic Details
Main Authors: M Mohajery, AA Shamsian, M Mahmoodi
Format: Article
Language:English
Published: Tehran University of Medical Sciences 2007-05-01
Series:Iranian Journal of Public Health
Subjects:
Tc1
Online Access:http://journals.tums.ac.ir/PdfMed.aspx?pdf_med=/upload_files/pdf/3149.pdf&manuscript_id=3149
id doaj-88d7a2e1ada24bc69b10ec04f1c21b79
record_format Article
spelling doaj-88d7a2e1ada24bc69b10ec04f1c21b792020-12-02T00:48:23ZengTehran University of Medical SciencesIranian Journal of Public Health2251-60852007-05-013615561Tc1 Cells Percentage in Patients with Cutaneous Leishmaniasis before and after Treatment with GlucantimeM MohajeryAA ShamsianM MahmoodiBackground: Various responses and different prognosis to specific treatment in different patients from one hand, and importance of IFN-γ producer cells on the other hand impressed us to study Tc1. Methods: The study was conducted in Ghaem Medical Center and Bu-Ali Research Institute, Mashhad University of Medical Sciences, Iran from 2001 to 2002. Lymphocytes of 36 patients were counted and cultured. Percentage of different responsible immunity cells in 29 patients, were determined by Flow Cytometry System before and after medication with glucantime (IM). Patients who showed improvement after the treatment were put into group 1 and those who did not recover were labeled group 2. In this self-control clinical trial, sampling method was consecutive non-probability and the results were analyzed by t-test consequently. Results: The percentage of Tc1 cells showed a significant increase despite of being stimulated with Phorpol-Mristate-Acetate (PMA) among the whole studied patients and group 1 (P= 0.069 and P= 0.040, respectively). While no significant change was observed among patients in group 2. Conclusion: This verifies the influence of Tc1 cells for the treatment of patients with CL and perhaps the role of glucantime in improving the cell immunity response through increasing such cells. http://journals.tums.ac.ir/PdfMed.aspx?pdf_med=/upload_files/pdf/3149.pdf&manuscript_id=3149Glucantime and lymphocyteTc1
collection DOAJ
language English
format Article
sources DOAJ
author M Mohajery
AA Shamsian
M Mahmoodi
spellingShingle M Mohajery
AA Shamsian
M Mahmoodi
Tc1 Cells Percentage in Patients with Cutaneous Leishmaniasis before and after Treatment with Glucantime
Iranian Journal of Public Health
Glucantime and lymphocyte
Tc1
author_facet M Mohajery
AA Shamsian
M Mahmoodi
author_sort M Mohajery
title Tc1 Cells Percentage in Patients with Cutaneous Leishmaniasis before and after Treatment with Glucantime
title_short Tc1 Cells Percentage in Patients with Cutaneous Leishmaniasis before and after Treatment with Glucantime
title_full Tc1 Cells Percentage in Patients with Cutaneous Leishmaniasis before and after Treatment with Glucantime
title_fullStr Tc1 Cells Percentage in Patients with Cutaneous Leishmaniasis before and after Treatment with Glucantime
title_full_unstemmed Tc1 Cells Percentage in Patients with Cutaneous Leishmaniasis before and after Treatment with Glucantime
title_sort tc1 cells percentage in patients with cutaneous leishmaniasis before and after treatment with glucantime
publisher Tehran University of Medical Sciences
series Iranian Journal of Public Health
issn 2251-6085
publishDate 2007-05-01
description Background: Various responses and different prognosis to specific treatment in different patients from one hand, and importance of IFN-γ producer cells on the other hand impressed us to study Tc1. Methods: The study was conducted in Ghaem Medical Center and Bu-Ali Research Institute, Mashhad University of Medical Sciences, Iran from 2001 to 2002. Lymphocytes of 36 patients were counted and cultured. Percentage of different responsible immunity cells in 29 patients, were determined by Flow Cytometry System before and after medication with glucantime (IM). Patients who showed improvement after the treatment were put into group 1 and those who did not recover were labeled group 2. In this self-control clinical trial, sampling method was consecutive non-probability and the results were analyzed by t-test consequently. Results: The percentage of Tc1 cells showed a significant increase despite of being stimulated with Phorpol-Mristate-Acetate (PMA) among the whole studied patients and group 1 (P= 0.069 and P= 0.040, respectively). While no significant change was observed among patients in group 2. Conclusion: This verifies the influence of Tc1 cells for the treatment of patients with CL and perhaps the role of glucantime in improving the cell immunity response through increasing such cells.
topic Glucantime and lymphocyte
Tc1
url http://journals.tums.ac.ir/PdfMed.aspx?pdf_med=/upload_files/pdf/3149.pdf&manuscript_id=3149
work_keys_str_mv AT mmohajery tc1cellspercentageinpatientswithcutaneousleishmaniasisbeforeandaftertreatmentwithglucantime
AT aashamsian tc1cellspercentageinpatientswithcutaneousleishmaniasisbeforeandaftertreatmentwithglucantime
AT mmahmoodi tc1cellspercentageinpatientswithcutaneousleishmaniasisbeforeandaftertreatmentwithglucantime
_version_ 1724410407419904000